IL2 and acute myeloid leukemia: According to post hoc analyses of phase 3 trial results, HDC durably reduces relapse risk among patients with AML of normal karyotype and in patients with leukemic cells responsive to initial chemotherapy; in these subgroups, treatment with HDC/LD-IL-2 largely doubles the likelihood of long-term relapse-free survival with a similar magnitude of efficacy for overall survival.